Skip to comments.The New York Genome Center and IBM Watson Group Announce Collaboration to Advance Genomic Medicine
Posted on 03/20/2014 9:43:58 PM PDT by Vince Ferrer
The New York Genome Center (NYGC) and IBM (NYSE: IBM) today announced an initiative to accelerate a new era of genomic medicine with the use of IBMs Watson cognitive system. IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients.
NYGC and its medical partner institutions plan to initially evaluate Watsons ability to help oncologists develop more personalized care to patients with glioblastoma, an aggressive and malignant brain cancer that kills more than 13,000 people in the U.S. each year. Despite groundbreaking discoveries into the genetic drivers of cancers like glioblastoma, few patients benefit from personalized treatment that is tailored to their individual cancer mutations. Clinicians lack the tools and time required to bring DNA-based treatment options to their patients and to do so, they must correlate data from genome sequencing to reams of medical journals, new studies and clinical records -- at a time when medical information is doubling every five years.
This joint NYGC Watson initiative aims to speed up this complex process, identifying patterns in genome sequencing and medical data to unlock insights that will help clinicians bring the promise of genomic medicine to their patients. The combination of NYGCs genomic and clinical expertise coupled with the power of IBMs Watson system will enable further development and refinement of the Watson tool with the shared goal of helping medical professionals develop personalized cancer care.
The new cloud-based Watson system will be designed to analyze genetic data along with comprehensive biomedical literature and drug databases. Watson can continually learn as it encounters new patient scenarios, and as more information becomes available through new medical research, journal articles and clinical studies. Given the depth and speed of Watsons ability to review massive databases, the goal of the collaboration is to increase the number of patients who have access to care options tailored to their diseases DNA.
Since the human genome was first mapped more than a decade ago, weve made tremendous progress in understanding the genetic drivers of disease. The real challenge before us is how to make sense of massive quantities of genetic data and translate that information into better treatments for patients, said Robert Darnell, M.D., Ph.D., CEO, President and Scientific Director of the New York Genome Center. Applying the cognitive computing power of Watson is going to revolutionize genomics and accelerate the opportunity to improve outcomes for patients with deadly diseases by providing personalized treatment.
First Watson Application in Genomic Research Watson will complement rapid genome sequencing and is expected to dramatically reduce the time it takes to correlate an individuals genetic mutations with reams of medical literature, study findings, and therapeutic indications that may be relevant. The intention is to provide comprehensive information to enable clinicians to consider a variety of treatment options that the clinician can tailor to their patients genetic mutations. It will also help NYGC scientists understand the data detailing gene sequence variations between normal and cancerous biopsies of brain tumors.
As genomic research progresses and information becomes more available, we aim to make the process of analysis much more practical and accessible through cloud-based, cognitive innovations like Watson, said Dr. John E. Kelly III, Senior Vice President and Director of IBM Research. With this knowledge, doctors will be able to attack cancer and other devastating diseases with treatments that are tailored to the patients and diseases own DNA profiles. If successful, this will be a major transformation that will help improve the lives of millions of patients around the world.
The goal is to have the Watson genomics prototype assist clinicians in providing personalized genomic analytics information as part of a NYGC clinical research study. The solution has been under development for the past decade in IBMs Computational Biology Center at IBM Research.
New York States Investment in Genomic Medicine New York State is at the forefront of advancing medical science and commercialization. Governor Andrew M. Cuomo recently proposed $105 million to fund a partnership between NYGC and the University at Buffalos Center for Computational Research to advance genomics research. This investment to enhance the states genomic medicine capabilities, together with NYGCs acquisition of Illuminas state-of-the-art HiSeq X Ten whole human genome sequencing system, will accelerate the availability of valuable genomic information in New York. New York States investment in cutting-edge innovative industries is creating jobs and growing the economy in Western New York and across our state, said Governor Cuomo. This collaboration between the New York Genome Center and IBM will help make the region a new hub for the growing bio-tech industry.
IBM is NYGCs Founding Technology Member and will advance the organizations goals of translating genomic research into clinical solutions for serious disease through the collaboration of medicine, science and technology. As biology increasingly becomes an information science, the promise of genomics is closer to reality with the help of data-driven analytics methods and more powerful computing systems. IBM and NYGCs computational biology experts are renowned for accelerating life sciences discoveries using deep analytical approaches and next generation information technologies.
Learn more about this story at http://ibm.co/1cXTb6u. To view a Flickr image gallery that illustrates todays news please click here.
For additional perspectives on this story, please watch this video.
To join the social conversation on Twitter use the hashtag #NYGCWatson.
Journalists and bloggers can download broadcast video, b-roll and photos about the Watson and New York Genome Center collaboration at http://bit.ly/1dcWlZF. The video is available in HD, standard definition broadcast and streaming quality.
About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve peoples lives - ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University, Cornell University/Weill Cornell Medical College, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, North Shore-LIJ, The Rockefeller University, Roswell Park Cancer Institute and Stony Brook University. For more information, visit: www.nygenome.org.
About IBM Watson
Named after IBM founder Thomas J. Watson, Watson was developed in IBMs Research labs and is now being accelerated into market by the new Watson Group. Watson represents a new class of software, services and apps that think, improve by learning, and discover answers and insights to complex questions from massive amounts of Big Data. Watsons ability to answer complex questions posed in natural language with speed, accuracy and confidence is transforming decision-making across a variety of industries, including health care, financial services and retail. IBM has advanced Watson from a game-playing innovation into a commercial technology. Using natural language processing and analytics, Watson processes information akin to how people think, representing a major shift in an organizations ability to quickly analyze, understand and respond to Big Data. Now delivered from the cloud and able to power new consumer and enterprise services and apps, Watson is 24 times faster, smarter with a 2,400 percent improvement in performance, and 90 percent smaller IBM has shrunk Watson from the size of a master bedroom to three stacked pizza boxes. IBM is investing $1 billion to introduce a new class of cognitive computing services, software and apps, and investing $100 million to spur innovation for software application providers to develop a new generation of Watson-powered solutions. Learn more about IBM Watson at www.ibmwatson.com. Learn more about IBM Research at www.research.ibm.com. Learn more about IBM healthcare at ibm.com/smarterhealthcare.
Watson is a big deal. When we think of technology taking away jobs, we think of low skill jobs being eliminated. Watson will take away jobs, and refocus may others, but these will be the highest skill jobs.
One of the first tasks IBM has wanted to train Watson to do is medical diagnosis. When a human is trained in medicine, they can only learn a subset of medical knowledge, and that information starts to become obsolete on graduation day. Watson can be trained on a database of all written medical knowledge, far more than can be read by one doctor in a lifetime. Furthermore, this knowledge is coninuously updated. If a scientist publishes research today, Watson will be using it to diagnose tomorrow.
Diagnosing a patient correctly is one of the most difficult tasks of a doctor, and one which requires the most training. This part of the doctor's skill will start to be replaced by machine.
This is the first wave of a new level of AI. Soon, any job that can be done completely by phone or email, will be capable of being done by an AI. While this is going to effect careers and jobs, it will also lead to many benefits. For the tasks given to Watson can be done by it far better than a human, no matter how long the training.
Watson (or even lesser systems) might be terrific research systems, but were I a doctor I wouldn’t just want an ipse dixit from the machine. I’d want it to give me an explanation why it’s suggesting something.
spell backwards this is A CAT TAG
We’re all cats now. Hopefully the tags won’t clash with my wardrobe.
All well and good except that nobody will benefit from it because it won't be covered by ObamaCare's primitive, no-coverage, ultra-expensive health insurance plans.